IP Library › Patent Application 15213341
Patent Application
App. No. 15/213,341

METHODS AND COMPOSITIONS EMPLOYING BICIFADINE FOR TREATING DISABILITY OR FUNCTIONAL IMPAIRMENT ASSOCIATED WITH ACUTE PAIN, CHRONIC PAIN, OR NEUROPATHIC DISORDERS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/213,341
Abstract

Methods and compositions are provided for formulating and administering bicifadine and related compounds to treat or prevent functional impairment and disabilities associated with acute pain, chronic pain, and neuropathic disorders.

Claims (15)

1 - 70 . (canceled)

71 . A method for treating chronic pain and/or neuropathic pain in a mammalian subject comprising administering to the mammalian subject a sustained release pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I

or a pharmaceutically acceptable salt thereof combined with a sustained release vehicle, matrix, binder, or coating material.

72 . The method of claim 71 , wherein the sustained release pharmaceutical composition comprises a therapeutically effective amount of 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane hydrochloride.

73 . The method of claim 71 , wherein the sustained release pharmaceutical composition comprises a therapeutically effective amount of (+)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof.

74 . The method of claim 71 , wherein the sustained release pharmaceutical composition comprises a therapeutically effective amount of (−)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof.

75 . The method of claim 71 , wherein the sustained release pharmaceutical composition comprises polymorph form B of 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane hydrochloride.

76 . The method of claim 71 , wherein the sustained release pharmaceutical composition comprises polymorph form A of 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane hydrochloride.

77 . A method for treating chronic pain in a mammalian subject comprising administering to the mammalian subject a therapeutically effective amount of a compound of Formula I

or a pharmaceutically acceptable salt thereof in a daily dosing regimen consisting of one or two doses of Formula I per day.

78 . The method of claim 77 comprising administering 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane hydrochloride.

79 . The method of claim 77 comprising administering (+)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof.

80 . The method of claim 77 comprising administering (+1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof.

81 . The method of claim 77 comprising administering polymorph form B of 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane hydrochloride.

82 . The method of claim 77 comprising administering polymorph form A of 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane hydrochloride.